PLoS ONE (Jan 2015)

Let-7, mir-98 and mir-183 as biomarkers for cancer and schizophrenia [corrected].

  • Emmanouil Rizos,
  • Nikolaos Siafakas,
  • Eleni Katsantoni,
  • Eleni Skourti,
  • Vassilios Salpeas,
  • Ioannis Rizos,
  • James N Tsoporis,
  • Anastasia Kastania,
  • Anastasia Filippopoulou,
  • Nikolaos Xiros,
  • Demetrios Margaritis,
  • Thomas G Parker,
  • Charalabos Papageorgiou,
  • Vassilios Zoumpourlis

DOI
https://doi.org/10.1371/journal.pone.0123522
Journal volume & issue
Vol. 10, no. 4
p. e0123522

Abstract

Read online

Recent evidence supports a role of microRNAs in cancer and psychiatric disorders such as schizophrenia and bipolar disorder, through their regulatory role on the expression of multiple genes. The rather rare co-morbidity of cancer and schizophrenia is an old hypothesis which needs further research on microRNAs as molecules that might exert their oncosuppressive or oncogenic activity in the context of their role in psychiatric disorders. The expression pattern of a variety of different microRNAs was investigated in patients (N = 6) suffering from schizophrenia termed control, patients with a solid tumor (N = 10) and patients with both schizophrenia and tumor (N = 8). miRNA profiling was performed on whole blood samples using the miRCURY LNA microRNA Array technology (6th & 7th generation). A subset of 3 microRNAs showed a statistically significant differential expression between the control and the study groups. Specifically, significant down-regulation of the let-7p-5p, miR-98-5p and of miR-183-5p in the study groups (tumor alone and tumorand schizophrenia) was observed (p<0.05). The results of the present study showed that let-7, miR-98 and miR-183 may play an important oncosuppressive role through their regulatory impact in gene expression irrespective of the presence of schizophrenia, although a larger sample size is required to validate these results. Nevertheless, further studies are warranted in order to highlight a possible role of these and other micro-RNAs in the molecular pathways of schizophrenia.